Latigo Biotherapeutics
Thousand Oaks
About Latigo Biotherapeutics
Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain at its source to provide effective, rapid-acting pain relief without the risk of addiction. Their lead program targets Nav1.8, a validated human pain target, leveraging internal ion channel expertise.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $300.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Mar 2025)
- Website: latigobio.com
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/latigo-biotherapeutics-35497 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.